Related Experiment Video
Updated: Jun 21, 2026
08:34
Field-Deployable Lens-Free Imaging Platform for Rapid Label-Free Analysis of Natural Killer Cell Activation
Published on: August 8, 2025
Complement-coupled erythrocyte platform for rapid enrichment of candidate NLRP3 modulators
Lijia Shi1, Wenjing Liu1, Xueman Xie1
1State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, East China University of Science and Technology, Shanghai, 200237, China.
Biochemical and Biophysical Research Communications
|June 19, 2026
Summary
A novel erythrocyte-based assay screens for NLRP3 modulators, overcoming limitations of traditional methods. This cost-effective platform rapidly identifies potential drug candidates for inflammatory diseases.
Area of Science:
- Immunology
- Pharmacology
Background:
- NLRP3 inflammasome is a key target for inflammatory diseases.
- Conventional screening methods for NLRP3 modulators are resource-intensive and technically challenging.
Purpose of the Study:
- To develop and validate a high-throughput screening platform for NLRP3 modulators using spectosis.
- To identify novel small molecules that modulate NLRP3 signaling via an erythrocyte-based assay.
Main Methods:
- Phenotypic screening platform based on spectosis (complement-driven erythrocyte death).
- Monitoring complement-mediated hemolysis for compound evaluation.
- Screening of 1000 small molecules, followed by three rounds of confirmatory screening.
- Counter-screening against C9 deposition and validation in THP-1 macrophages.
Main Results:
- 365 initial active compounds identified from 1000 screened molecules.
- 11 validated hits consistently passed confirmatory screening.
- Ten of eleven hits did not suppress complement C9 deposition, suggesting non-direct complement inhibition.
- Five candidates showed efficacy in attenuating IL-1β maturation and LDH release in macrophages.
Conclusions:
- The erythrocyte-based spectosis assay is a rapid and cost-effective method for enriching NLRP3 modulator candidates.
- This platform overcomes the throughput limitations of conventional macrophage-based assays.
- Identified compounds warrant further investigation for treating NLRP3-mediated inflammatory disorders.
